CDK inhibitors and methods of use thereof
Compounds targeting CDK12 and CDK13 kinases, as represented by Formulas I through I-H, address the need for new cancer therapies by inhibiting these kinases, enhancing the effectiveness of cancer treatments.
WO2026136733A1PCT designated stage Publication Date: 2026-06-25DECIPHERA PHARMACEUTICALS LLC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- DECIPHERA PHARMACEUTICALS LLC
- Filing Date
- 2025-12-18
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
There is a need for new targeted therapies that inhibit or impair the function of CDK12 and CDK13 to overcome resistance to chemotherapy and targeted agents in cancer treatment, as these kinases play a crucial role in transcriptional regulation, DNA damage response, and tumor cell survival.
Method used
Development of compounds represented by Formulas I through I-H, which are CDK12 and/or CDK13 inhibitors, potentially used alone or in combination with other active agents, to target and impair the kinase activity of these proteins.
Benefits of technology
These compounds effectively inhibit CDK12 and/or CDK13, offering potential therapeutic benefits in treating cancer by sensitizing tumor cells to DNA damaging agents and overcoming resistance to targeted therapies.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060427_25062026_PF_FP_ABST
Abstract
Described herein are compounds that are inhibitors of CDK12 and / or CDK13 and their use in the treatment of disorders such as cancers.
Need to check novelty before this filing date? Find Prior Art